| Title |
The Availability, Pricing and Affordability of Three Essential Asthma Medicines in 52 Low- and Middle-Income Countries
|
|---|---|
| Published in |
PharmacoEconomics, October 2013
|
| DOI | 10.1007/s40273-013-0095-9 |
| Pubmed ID | |
| Authors |
Zaheer-Ud-Din Babar, Charon Lessing, Cécile Mace, Karen Bissell |
| Abstract |
Almost 300 million people suffer from asthma, yet many in low- and middle-income countries have difficulty accessing essential asthma medicines. Availability, price and affordability of medicines are likely to affect access. Very few studies have included asthma medicines, particularly inhaled corticosteroids, in these countries. Reflections about international reference prices (IRPs) are generally absent from pricing studies, yet some IRPs may be masking the extent of access problems. |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 17% |
| United States | 2 | 11% |
| Pakistan | 1 | 6% |
| Canada | 1 | 6% |
| Argentina | 1 | 6% |
| New Zealand | 1 | 6% |
| Unknown | 9 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 61% |
| Science communicators (journalists, bloggers, editors) | 3 | 17% |
| Practitioners (doctors, other healthcare professionals) | 2 | 11% |
| Scientists | 2 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 165 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| United States | 1 | <1% |
| South Africa | 1 | <1% |
| Unknown | 162 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 37 | 22% |
| Researcher | 22 | 13% |
| Student > Ph. D. Student | 16 | 10% |
| Student > Doctoral Student | 13 | 8% |
| Student > Postgraduate | 9 | 5% |
| Other | 28 | 17% |
| Unknown | 40 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 46 | 28% |
| Pharmacology, Toxicology and Pharmaceutical Science | 24 | 15% |
| Social Sciences | 15 | 9% |
| Nursing and Health Professions | 8 | 5% |
| Economics, Econometrics and Finance | 6 | 4% |
| Other | 23 | 14% |
| Unknown | 43 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 July 2020.
All research outputs
#1,420,040
of 26,017,215 outputs
Outputs from PharmacoEconomics
#55
of 2,012 outputs
Outputs of similar age
#12,821
of 228,159 outputs
Outputs of similar age from PharmacoEconomics
#1
of 24 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,012 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,159 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.